Group 1 - The company, Haohai Biological Technology, announced its participation in a collective performance briefing for the biopharmaceutical and CXO industry hosted by the Shanghai Stock Exchange [2] - The event is scheduled for September 15, 2025, from 15:00 to 17:00 [2]

Group 1 - The "2025 Ophthalmic Medical Engineering Transformation Innovation Summit" was held in Hangzhou, focusing on the integration of medical and engineering innovations in the ophthalmic field [1][3] - The summit gathered industry experts and representatives to discuss the latest trends, challenges, and solutions in medical technology transformation, aiming to enhance the industrialization of medical technology achievements [1][2] - The Chinese ophthalmic medical device market has surpassed 200 billion yuan in 2024, with a high dependence on imported high-value consumables, reaching nearly 70% [2] Group 2 - The summit featured two core agendas: "Gathering Strengths and Coexistence" and "Chain Movement and Innovation," focusing on policy guidance and technological innovation in key areas such as ophthalmic technology development and cataract treatment [3] - Significant achievements in medical-engineering transformation were showcased, including the development of a new type of artificial lens and innovative non-invasive cataract treatment devices, supported by national key research projects [3][4] - The establishment of the "Medical-Engineering Integration Innovation Alliance" during the summit marks a new phase for clinical transformation projects in ophthalmology, supported by regulatory, industrial, and clinical collaboration [3][4] Group 3 - The summit emphasized the importance of collaboration between clinical medicine and engineering technology to overcome barriers and enhance the practical application of innovative ideas [4] - The company, Haohai Biological Technology, has developed a comprehensive transformation system covering raw material research, process innovation, clinical validation, and product transformation, aiming to enhance the quality of ophthalmic healthcare [4][5] - Haohai aims to accelerate the domestic production process of high-end technologies and provide comprehensive solutions for eye health, contributing to the "Healthy China 2030" initiative [5] Group 4 - The Shanghai Yangtze River Delta Medical Device Industry Development Promotion Association aims to promote innovation and development in the medical device industry, facilitating collaboration among enterprises, research institutions, and medical organizations [6] - Haohai Biological Technology is a leading company in the ophthalmic field, focusing on the research, development, and production of medical devices and pharmaceuticals using biomedicine and genetic engineering technologies [7] - The company has established a global presence and aims to enhance its competitive edge in the ophthalmic medical device market through innovation and integration of high-quality raw materials [7]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司關 於參加2025年半年度科創板生物製品及CXO行業集體業績說明會的公告》，僅供 參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年9月5日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及 唐敏捷先生；本公司之非執行董事為游捷女士、黃明先生及魏長征先生；及本公 司之獨立非執行董事為沈紅波先生、姜志宏先生、蘇治先生及楊玉社先生。 * 僅供識別 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 本公司董事 ...

Group 1 - The company, Shanghai Haohai Biological Technology Co., Ltd., will participate in the 2025 semi-annual performance briefing for the biopharmaceutical and CXO industry organized by the Shanghai Stock Exchange to enhance communication with investors [1][2] - The performance briefing is scheduled for September 15, 2025, from 15:00 to 17:00, and will be conducted via video live streaming and online interaction [1][2] - Investors are encouraged to submit questions from September 8 to September 12, 2025, through the Shanghai Stock Exchange Roadshow Center website or via the company's email [2] Group 2 - Key participants in the briefing will include the company's chairman, general manager, financial officer, independent directors, and the board secretary, although adjustments may occur due to special circumstances [2] - After the briefing, investors can access the main content and details of the event through the Shanghai Stock Exchange Roadshow Center [2]

证券代码：688366 证券简称：昊海生科 公告编号：2025-041 上海昊海生物科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、说明会类型 上海昊海生物科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 23 日在上海证券交易所网站（www.sse.com.cn）披露了《上海昊海生物科技股份有 限公司 2025 年半年度报告》。为加强与投资者的深入交流，使投资者更加全面、 深入地了解公司情况，公司参加由上海证券交易所主办的 2025 年半年度科创板 生物制品及 CXO 行业集体业绩说明会（以下简称"本次业绩说明会"），此次活 动将以视频直播和网络互动的方式召开，欢迎广大投资者积极参与。公司现就本 次业绩说明会提前向广大投资者征集相关问题，广泛听取投资者的意见和建议。 二、说明会召开的时间及方式 本次业绩说明会将于 2025 年 9 月 15 日（星期一）15:00-17:00 在上证路演 会议召开时间：2025 年 9 月 15 日（星期一）15:00-17:00 会议 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 | | | 備註： 第 1 頁 共 11 頁 v 1.1.1 公司名稱: 上海昊海生物科技股份有限公司 (「本公司」)（於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 1. 股份分類 普通股 股份類別 H 於香港聯交所上市 (註1) 是 證券代號 (如上市) 06826 說明 H股 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 38,529,240 RMB 1 RMB 38,529,240 增加 / 減少 (-) 0 RMB 0 本月底結存 38,529,240 RMB 1 RMB 38,529,240 | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | | A股 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 公司名稱: 上海昊海生物科技股份有限公司 (「本公司」)（於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 1. 股份分類 普通股 股份類別 H 於香港聯交所上市 (註1) 是 證券代號 (如上市) 06826 說明 H股 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 38,529,240 RMB 1 RMB 38,529,240 增加 / 減少 (-) 0 RMB 0 本月底結存 38,529,240 RMB 1 RMB 38,529,240 | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | | A股（上海證券交易所科創板，股份代號：688366） | | | | | | | | 法定/註冊 ...

Group 1 - The core viewpoint of the article is that Haohai Biological's revenue and net profit have declined in the first half of 2025, indicating challenges in its key business segments, particularly in medical aesthetics and ophthalmology [1][2][3] - The company reported a revenue of 1.304 billion yuan, a year-on-year decrease of 7.12%, and a net profit attributable to shareholders of 211 million yuan, down 10.29% [1][2] - The main product segments, including medical aesthetics, ophthalmology, and orthopedics, all experienced revenue declines, with medical aesthetics generating 575 million yuan, down 9.31%, ophthalmology 368 million yuan, down 18.61%, and orthopedics 227 million yuan, down 2.58% [2][3] Group 2 - The decline in the hyaluronic acid business is attributed to changes in VAT rates affecting sales revenue and weak sales of entry-level products, which have not sustained their market advantage for nearly a decade [3][4] - The company’s high-end products, such as the third-generation and fourth-generation hyaluronic acid series, are performing well, but the overall medical aesthetics business may face negative growth for the first time this year [5][6] - The ophthalmology segment has seen significant revenue drops, particularly in cataract surgery products, which fell by 28.76%, largely due to national medical cost control policies [6][7] Group 3 - The company is actively responding to declining performance by focusing on high-end products and has seen a 73.82% increase in sales of mid-range pre-filled non-spherical products [9][10] - The competitive landscape in the medical aesthetics market is challenging, with several leading companies reporting similar revenue declines, indicating a broader industry adjustment [5][6] - The strategic shift towards mid-to-high-end products is seen as an opportunity, but the company faces challenges in product development and market penetration due to strong competition from imported brands [9][10]

Core Viewpoint - Haohai Biological Technology (688366) reported a decline in both revenue and net profit for the first half of 2025 compared to the same period in 2024, indicating potential challenges in its financial performance and operational efficiency [1] Financial Performance Summary - Total revenue for the first half of 2025 was 1.304 billion yuan, a decrease of 7.12% year-on-year [1] - Net profit attributable to shareholders was 211 million yuan, down 10.29% year-on-year [1] - In Q2 2025, total revenue was 686 million yuan, reflecting a 9.57% decline year-on-year [1] - Q2 net profit attributable to shareholders was 121 million yuan, a decrease of 12.33% year-on-year [1] - Gross margin stood at 70.17%, a slight decrease of 0.49% year-on-year [1] - Net margin was 15.46%, down 0.24% year-on-year [1] - Total operating expenses (selling, administrative, and financial) amounted to 566 million yuan, accounting for 43.39% of revenue, an increase of 3.38% year-on-year [1] Balance Sheet Highlights - Cash and cash equivalents decreased to 2.562 billion yuan, down 3.93% year-on-year [1] - Accounts receivable slightly decreased to 333 million yuan, a decline of 0.92% year-on-year [1] - Interest-bearing liabilities increased to 416 million yuan, up 3.19% year-on-year [1] - Net asset value per share was 24.06 yuan, a decrease of 0.37% year-on-year [1] - Earnings per share fell to 0.91 yuan, down 9.90% year-on-year [1] - Operating cash flow per share was 1.3 yuan, a decrease of 6.89% year-on-year [1] Cash Flow Analysis - Net cash flow from investing activities showed a significant decline of 455.44%, primarily due to net outflows related to new large bank deposits [2] - Net cash flow from financing activities decreased by 87.47%, attributed to the absence of cash inflows from new share issuance and increased cash outflows related to share buybacks and privatization activities [2] Business Evaluation - The company's Return on Invested Capital (ROIC) for the previous year was 5.01%, indicating average capital returns [3] - Historical data shows a median ROIC of 8.49% since the company went public, suggesting a generally favorable investment return [3] - The company's net profit margin was reported at 13.95%, indicating a high value-added from its products or services [3] Business Model Insights - The company's performance is primarily driven by marketing efforts, necessitating a thorough examination of the underlying factors influencing this drive [4]

Core Viewpoint - The company, Haohai Biological Technology Co., Ltd., has reported a decline in its financial performance for the first half of 2025, with a focus on revenue and profit reductions, while also announcing a cash dividend distribution plan for shareholders [2][4]. Financial Performance Summary - For the first half of 2025, the company's main revenue was 1.304 billion yuan, a year-on-year decrease of 7.12% [2][6]. - The net profit attributable to shareholders was 211 million yuan, down 10.29% year-on-year [2][6]. - The net profit after deducting non-recurring gains and losses was 204 million yuan, a decline of 11.35% compared to the previous year [2][6]. - In Q2 2025, the company reported a single-quarter main revenue of 686 million yuan, a decrease of 9.57% year-on-year [2][6]. - The single-quarter net profit attributable to shareholders was 121 million yuan, down 12.33% year-on-year [2][6]. - The company's debt ratio stood at 18.14%, with investment income recorded at -28,700 yuan and financial expenses at 30.89 million yuan [2][6]. - The gross profit margin was reported at 70.17% [2][6]. Company Announcements Summary - The company’s subsidiary, Haohai Biological Technology Holdings Co., Ltd., has terminated its exclusive distribution agreement with Hengtai Optical and Hengtai Vision due to Hengtai Optical's acquisition by Carl Zeiss [3]. - As part of the termination agreement, Hengtai Optical's major shareholders will pay 80 million yuan as a termination compensation [3]. - Hengtai Vision reported total assets of 11.52 million yuan, net assets of 5.06 million yuan, and an operating income of 18.85 million yuan, with a net loss of 3.65 million yuan for the first half of 2025 [3]. - The company plans to increase market promotion for its self-developed OK lens products and optimize product structure [3]. - The cash dividend distribution plan for the first half of 2025 is set at 4.00 yuan per 10 shares (including tax), totaling 91.49 million yuan, which accounts for 43.35% of the net profit attributable to shareholders [4][6].